Clin2
NCT07038746Possibly a fitRecruiting

Inhaled epinephrine for severe allergic reactions during tests or treatment

HypersensitivityAnaphylaxis

Part of Immune system & allergy clinical trials.

This trial tests if inhaled epinephrine can safely treat moderate to severe allergic reactions (grade 2 or higher) that can happen during allergy skin tests, oral food or drug challenges, or allergy shots. It is for people who have had such reactions in the past or are at risk and are planning to undergo one of these procedures.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1
Enrollment
100 people
Ages
12 years and older
Study type
Interventional

Who can take part

  • You are at least 12 years old.
  • You have a known or suspected allergy, confirmed by a positive skin test or blood test for allergen-specific IgE (the type of antibody involved in immediate allergic reactions).
  • You have had a moderate to severe allergic reaction (grade 2 or higher) during a past allergy test, oral challenge, or allergy shot session, or you are scheduled for such a procedure and may have a similar reaction.
  • If you are a woman who could become pregnant, you must not be pregnant or breastfeeding and must agree to use an effective method of birth control from screening until the end of the study.
  • You are not allergic to epinephrine or any ingredient in the study drug.
  • You do not have any other medical condition that would make participation unsafe or interfere with the study results, and you are not currently taking part in another interventional drug or biologic study.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07228325Enrolling by invitation· Phase 1/Phase 2
Comparing a new epinephrine injector to EpiPen in adults with allergies

This study tests a new epinephrine auto-injector (FMXIN002) compared to the standard EpiPen in people with a history of hay fever or seasonal allergies. The goal is to see if the new device works just as well and is safe in a controlled clinic setting.

Mississauga
NCT07341776Recruiting· Phase 4
Testing steroids for food allergy reactions

This trial tests whether using a steroid drug can help treat allergic reactions to food. If you have a food allergy that causes immediate symptoms (like hives or trouble breathing), this study may help find better ways to manage those reactions.

Basel, Basel
NCT06834165Recruiting· Phase 4
Study of neffy vs. epinephrine shots for allergic reactions

This study compares a new nasal spray (neffy) to a standard epinephrine shot for treating severe allergic reactions during food challenges or allergy immunotherapy. It aims to see if the spray works as well and is safe.

La Jolla, California
NCT07045701Enrolling by invitation· Phase 2/Phase 3
Testing FMXIN002 for food allergy reactions

This study is testing a new medicine (FMXIN002) for people who are at risk of a severe allergic reaction to food. If you have a known food allergy and have had a moderate reaction during a food challenge, you may be able to join. The trial will check if the medicine helps prevent or reduce the severity of future reactions.

Be’er Ya‘aqov
NCT06317909Recruiting
New test for airway inflammation after allergen challenge in mild asthma

This study tests a new, non-invasive way to measure airway inflammation after breathing in an allergen (like pollen or dust mite). It is for people with mild asthma that is well controlled with only a rescue inhaler.

Hanover, Lower Saxony
NCT04163562Recruiting· Phase 1/Phase 2
Oral peanut treatment trial for people with peanut allergy

This trial tests an oral (by mouth) immune treatment for people with confirmed peanut allergy. It aims to see whether your immune system can become less reactive to peanuts over time, while keeping you safe during testing with careful emergency planning.

Pamplona, Navarre

Hear when a new Hypersensitivity trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.